Jump To

ZTALMY SIDE EFFECTS

  • Generic Name: ganaxolone oral suspension
  • Brand Name: Ztalmy
  • Drug Class: GABA Analogs
Last updated on MDtodate: 10/11/2022

SIDE EFFECTS

The following important adverse reactions are described elsewhere in the labeling:

  • Somnolence and Sedation
  • Suicidal Behavior and Ideation
  • Withdrawal of Antiepileptic Drugs

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In controlled and uncontrolled trials in patients with seizures associated with CDD, 102 patients were treated with ZTALMY, including 83 patients treated for more than 6 months, and 50 patients treated for more than 1 year.

In Study 1, 50 patients received ZTALMY. The duration of treatment in this trial was up to 17 weeks. Approximately 78% of these patients were female, 92% were White, and the mean age was 6.8 years (range 2 to 19 years). All patients receiving ZTALMY, except 1, were taking other AEDs. Adverse reactions in these patients are presented below.

The most common adverse reactions (an incidence of at least 5% and at least twice the rate of placebo) were somnolence, pyrexia, salivary hypersecretion, and seasonal allergy (Table 4).

The adverse reactions leading to treatment discontinuation in ZTALMY-treated patients were somnolence and seizure (1 patient) and seizure (1 patient).

Twenty-two percent of ZTALMY-treated patients had dosing interrupted or reduced because of any adverse reaction, compared to 16% of placebo-treated patients. The most frequent adverse reactions leading to a dose interruption or reduction in ZTALMY-treated patients were somnolence (10%) and sedation (2%).

Table 1 presents the adverse reactions that occurred in ZTALMY-treated patients with seizures associated with CDD at a rate of at least 3% and at a rate greater than in placebo-treated patients during the double-blind phase.

Table 1 : Adverse Reactions that Occurred in ZTALMY-Treated Patients with Seizures Associated with CDD at a Rate of At Least 3% and Greater Than in Placebo (Study 1)

 

Adverse Reactions ZTALMY
(N=50) %
Placebo
(N=51) %
Somnolence* 38 20
Pyrexia 18 8
Upper respiratory tract infection 10 6
Sedation 6 4
Salivary Hypersecretion 6 2
Seasonal allergy 6 0
Bronchitis 4 0
Influenza 4 2
Gait disturbance 4 2
Nasal congestion 4 2
* somnolence includes the terms lethargy and hypersomnia

 

SRC: NLM .

Read Next Article

PHP Code Snippets Powered By : XYZScripts.com